1-3 of 3
Stephan Stilgenbauer
Close
Sort by
Journal Articles

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Clinical Trials & Observations
Stephan Stilgenbauer, Eugen Tausch, Andrew W. Roberts, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P. Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T. Ghanim, Michael Moran, Wendy J. Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G. Wierda, John F. Seymour
Journal: Blood Advances
Blood Adv (2024) 8 (8): 1992–2004.
https://doi.org/10.1182/bloodadvances.2023011741
Published: 2024
Includes: Supplemental data
Journal Articles

Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL

Constantine Tam, Javier Pinilla-Ibarz, Carolina G. Castillo, Ana Cristina Fenili, Kathryn Huntley, Volkan Karakus, Mervat Mattar, Miguel A. Miroli, Catherine Moura, Miguel Pavlovsky, Fernando Piotrowski, Martin Šimkovič, Stephan Stilgenbauer
Journal: Blood Advances
Blood Adv (2023) 7 (22): 6819–6828.
https://doi.org/10.1182/bloodadvances.2023010879
Published: 2023
Includes: Supplemental data
Journal Articles

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors

Jialei Qi, Sascha Endres, Deyan Yordanov Yosifov, Eugen Tausch, Rashmi Priyadharshini Dheenadayalan, Xiang Gao, Annika Müller, Christof Schneider, Daniel Mertens, Peter Gierschik, Martin Wist, Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5698–5702.
https://doi.org/10.1182/bloodadvances.2022008955
Published: 2023
Includes: Supplemental data